Optimisation of bacteriophage M13-based DNA and chimeric (DNA/ protein) vaccines

基于噬菌体 M13 的 DNA 和嵌合（DNA/蛋白质）疫苗的优化

• 批准号: 710296
• 金额: $ 12.1万
• 依托单位: BIGDNA LTD
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710296
• 关键词: Optimisation; bacteriophage; M13; based; DNA

Bacteriophage (phage) offer the potential to deliver both protein and DNA vaccines within thesame construct. They also promise extremely rapid development and manufacturingtimescales, since the DNA vaccine cassette can be synthesised to express antigens forvirtually any pathogen, literally within days following sequence identification. Phage areextremely robust, and can be delivered orally or in combination with other vaccines, andbeing particulate antigens, are naturally targeted to antigen presenting cells.BigDNA holds patents surrounding bacteriophage-based DNA and DNA/protein (chimeric)vaccines. To date, our focus has been on using bacteriophage lambda. The company nowwishes to explore the potential for using phage M13 as an alternative vehicle for thistechnology. M13 is extremely well characterised with an excellent manufacturing base, andoffers enormous technological potential. Phage-based DNA vaccine technology has beendeveloped and patented by BigDNA in the UK, and has already attracted overseas investment,commercial collaborative R & D activity, and a licensing agreement with big pharma.This project aims to investigate the potential of a range of modifications designed to optimiseand develop M13 as a platform for this purpose which should result in a vaccine platform andproducts capable of addressing a wide range of infectious diseases and cancers for whichcurrent vaccines either do not exist, or alternatively, cannot be developed in the rapidtimescales likely required for pandemic disease indications.

噬菌体（噬菌体）提供了在同一构建体中递送蛋白质和DNA疫苗的潜力。它们还保证了极其快速的开发和制造时间尺度，因为DNA疫苗盒可以被合成以表达几乎任何病原体的抗原，实际上在序列鉴定后的几天内。噬菌体非常强大，可以口服或与其他疫苗联合使用，并且是颗粒抗原，天然靶向抗原呈递细胞。BigDNA拥有基于噬菌体的DNA和DNA/蛋白质（嵌合）疫苗的专利。到目前为止，我们的重点一直是使用λ噬菌体。该公司现在希望探索使用噬菌体M13作为这项技术的替代载体的潜力。M13拥有出色的制造基础，并具有巨大的技术潜力。基于噬菌体的DNA疫苗技术已由英国BigDNA公司开发并获得专利，并已吸引了海外投资，商业合作研发活动，该项目旨在研究一系列旨在优化和开发M13作为此目的平台的修改的潜力，这将导致疫苗平台和产品能够解决广泛的问题。传染病和癌症，目前的疫苗要么不存在，要么无法在大流行病适应症可能需要的快速时间范围内开发出来。